Glomerulonephritis Kidney TransplantNCT07783737

China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational Study

An observational study of Glomerulonephritis Kidney Transplant, run by AstraZeneca at 9 sites in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and older
Conditions the study is for: Glomerulonephritis Kidney Transplant
How many people: 300 participants
Where: 9 sitesChina
Study dates: 1 Oct 2026to 29 Aug 2030
Phase: Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Study population: Patients with a confirmed diagnosis of primary GN before kidney transplantation

Who may be able to join

Age ≥ 18 years.
Diagnosed with primary GN based on clinical guidelines and/or expert consensus
Successfully matching completed and confirmed to be scheduled for kidney transplantation.

Who cannot join

History of organ transplantation or planned multiple organ transplantation.
Complicated with malignancy.
Failure to undergo kidney transplantation for any reason.
Unable to provide written informed consent form (ICF).

Trial locations and contacts

9 sites in 1 country. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

City, postcode or hospital

Sites recruiting now only

9 sites in 1 country

China9 sites, 8 recruiting

Research Site
Beijing, Beijing Municipality
Not yet recruiting
Research Site
Guangzhou, Guangdong
Not yet recruiting
Research Site
Nanning, Guangxi
Recruiting
Research Site
Shanghai, Shanghai Municipality
Terminated
Research Site
Taiyuan, Shanxi
Not yet recruiting
Research Cite
Tianjin, Tianjin Municipality
Not yet recruiting
Research Site
Wuhan, Hubei
Not yet recruiting
Research Site
Yantai, Shandong
Not yet recruiting
Research Site
Zhengzhou, Henan
Not yet recruiting

Other trials in China

About this study

This is a prospective observational study aimed at establishing a prospective observational cohort of patients with a confirmed diagnosis of glomerulonephritis (GN) before kidney transplantation in China. Information will be collected on the epidemiology of GN recurrence after kidney transplantation, as well as the outcomes and treatment of the primary disease following kidney transplantation, to provide evidence for subsequent clinical studies, drug development, and translational research.

Approximately 300 patients with a confirmed diagnosis of GN before transplantation will be prospectively enrolled. Clinical data will be collected during screening, kidney transplantation, and a 3-year post-transplant follow-up. The frequency of follow-up visits is every 3 months in the 1st year after transplantation, and every 6 months during the 2nd to 3rd years, with a total of 8 follow-up visits. The study will be conducted at 10 sites across China.

Conditions: Glomerulonephritis Kidney Transplant
Keywords: glomerulonephritis, GN
Medical subject headings: Glomerulonephritis

What is being measured

The primary outcome is the main question the study is designed to answer.

To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
Incidence of GN recurrence after kidney transplantation
Measured: 3-year follow-up
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
Time to GN recurrence after kidney transplantation (months)
Measured: 3-year follow-up
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
Factors associated with GN recurrence after kidney transplantation
Measured: 3-year follow-up

Secondary outcomes (3)

To assess other clinical events after kidney transplantation and their associated factors
incidence and time to rejection
Measured: 3-year follow-up
To assess other clinical events after kidney transplantation and their associated factors
incidence and time to renal allograft loss
Measured: 3-year follow-up
To assess other clinical events after kidney transplantation and their associated factors
incidence and time to death
Measured: 3-year follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Oct 202629 Aug 2030

First posted25 Aug 2026
Study start1 Oct 2026
Primary completion29 Aug 2030 (estimated)
Study completion29 Aug 2030 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Glomerulonephritis Kidney TransplantStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Case only
Time perspective: Prospective
Enrolment: 300 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07783737
Sponsor's protocol ID: D9030R00002
Status last verified: Oct 2026
First submitted: 21 Aug 2026
Last updated: 21 Oct 2026
Results posted: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.